Studies of association between use of proton pump inhibitors (PPI) and dementia have yielded conflicting results.
Dr Mette Wod and colleagues investigated the effects of PPIs on cognitive decline in a study of middle-aged and elderly twins in Denmark.
In a prospective study, the team collected data from surveys of middle-aged individuals and older individuals who underwent cognitive assessments over a 10-year period or a 2-year period.
The research team determined cumulative use of PPIs 2 years prior study enrollment and during follow up, in defined daily doses (DDDs) of PPIs, using data from a nationwide prescription register.
Multi-variable linear regression models were used to examine associations between cumulative PPI use and a composite score of cognitive function at baseline and decreases in scores during the follow-up periods.
|Individuals with high consumption of PPI had higher adjusted scores than non-users|
|Clinical Gastroenterology & Hepatology|
Use of PPIs before study enrollment was associated with a slightly lower mean cognitive score at baseline in the middle age study.
The adjusted difference in mean score of individuals with high consumption of PPIs (≥400 DDD) was lower than that of non-users in the middle-age study.
In the longitudinal study of aging twins, individuals with high consumption of PPI had higher adjusted scores than non-users.
In analyses of cognitive decline, among individuals with high consumption of PPIs in the longitudinal study of aging, the adjusted mean difference between baseline score and follow-up score was lower than that of non-users.
The research team found that in the middle-age study, users with the highest consumption of PPIs (≥1600 DDD) had slightly less cognitive decline than non-users.
The team observed no significant stated differences in scores between PPI users and non-users.
Dr Wod's team concluded, "In analyzing data from 2 large population-based studies of twins in Denmark, we found no association between PPI use and cognitive decline."